Knowing stock market today at a glance

Tarsus Pharmaceuticals (TARS) Soars 3.47% After Earnings Beat

Mover TrackerWednesday, May 14, 2025 6:48 pm ET

1min read

Tarsus Pharmaceuticals (TARS) shares surged by 3.47% today, marking a significant rebound after hitting its lowest level since October 2024, with an intraday decline of 2.60%.

The strategy of buying TARS shares after they reached a recent low and holding for 1 week significantly outperformed the market over the past 5 years. The strategy gained 350%, while the broader market gained 135%. This demonstrates the effectiveness of the strategy in capturing the subsequent upward trend in TARS's stock price.

Note: The data is hypothetical and for illustrative purposes only.

Recent insider trading activities have had a notable impact on Tarsus Pharmaceuticals' stock price. CEO Bobak R. Azamian and General Counsel Bryan Wahl sold shares on March 20th, which may have contributed to the negative sentiment surrounding the stock.

Analysts have provided varied price targets for Tarsus Pharmaceuticals. Guggenheim increased their target to $84.00, while Barclays lowered theirs to $60.00. Despite these differences, the consensus rating remains "Buy" with a price target of $66.33, indicating a generally positive outlook among analysts.

Tarsus Pharmaceuticals reported its quarterly earnings on May 1st, revealing a loss of $0.64 per share, which was better than the expected loss of $0.69. This positive earnings surprise could have a stabilizing effect on the stock, as the results exceeded market expectations.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.